Pazopanib

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Locally Advanced and/or Metastatic Renal Cell Carcinoma

Conditions

Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma

Trial Timeline

Jan 24, 2012 → Jul 31, 2017

NCT ID

NCT01521715

About Pazopanib

Pazopanib is a approved stage product being developed by Novartis for Locally Advanced and/or Metastatic Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01521715. Target conditions include Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma.

What happened to similar drugs?

4 of 20 similar drugs in Locally Advanced and/or Metastatic Renal Cell Carcinoma were approved

Approved (4) Terminated (1) Active (15)

✅letrozoleJiangsu Hengrui MedicineApproved

✅FulvestrantAstraZenecaApproved

✅LetrozoleNovartisApproved

✅Trastuzumab emtansineRocheApproved

🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3

🔄Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3

🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03200717	Phase 2	Completed	Nov 14, 2017	Aug 10, 2021	Advanced Renal Cell Carcinoma
NCT02193152	Phase 2	Terminated	Apr 27, 2015	Dec 24, 2019	Carcinoma, Non-Small Cell Lung
NCT02300545	Phase 2	Completed	Apr 8, 2015	Jul 11, 2020	Sarcoma, Soft Tissue
NCT01956669	Phase 2	Completed	Oct 8, 2014	Nov 5, 2019	Solid Tumours
NCT01832259	Phase 2	Completed	Aug 1, 2013	Aug 9, 2018	Adenocarcinoma of the Prostate
NCT01759303	Phase 2	Terminated	Apr 1, 2013	May 1, 2017	Osteosarcoma
NCT01642017	Phase 1	Terminated	Nov 22, 2012	Mar 1, 2018	Metastatic Cancer (Different Solid Tumour Types)
NCT01649778	Pre-clinical	Completed	Jul 19, 2012	Jul 3, 2017	Carcinoma, Renal Cell
NCT01506596	Phase 2	Completed	Mar 1, 2012	Mar 1, 2016	Liposarcoma
NCT01521715	Approved	Completed	Jan 24, 2012	Jul 31, 2017	Locally Advanced and/or Metastatic Renal Cell Carcinoma
NCT01361334	Phase 2	Completed	Jun 1, 2011	Mar 1, 2016	Acute Myeloid Leukemia
NCT01566747	Phase 2	Completed	Mar 1, 2011	Jul 15, 2020	Renal Cell Carcinoma
NCT00387205	Phase 1	Completed	Jun 20, 2006	Mar 8, 2018	Carcinoma, Renal Cell

Competing Products

20 competing products in Locally Advanced and/or Metastatic Renal Cell Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	35
NBTXR3	Nanobiotix	Phase 1/2	33
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	29
SPYK04	Chugai Pharmaceutical	Phase 1	33
LUNA18 + Cetuximab	Chugai Pharmaceutical	Phase 1	21
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + Gemcitabine	Chugai Pharmaceutical	Phase 3	40
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + Pemetrexed	Daiichi Sankyo	Phase 3	44
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + Rilvegostomig	Daiichi Sankyo	Phase 1	36
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin	Astellas Pharma	Phase 1/2	39
zolbetuximab	Astellas Pharma	Pre-clinical	30
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	39
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	44
enfortumab vedotin (EV)	Astellas Pharma	Pre-clinical	26
zolbetuximab	Astellas Pharma	Pre-clinical	33
zolbetuximab + oxaliplatin + capecitabine + placebo	Astellas Pharma	Phase 3	44
ASP3082	Astellas Pharma	Phase 2	42
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + Placebo	Astellas Pharma	Phase 3	47
ASP1948	Astellas Pharma	Phase 1	29
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )	Sun Pharmaceutical	Phase 2	31